We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 24, 2019

Tumor Treating Fields Plus Chemotherapy as First-Line Therapy for Unresectable Malignant Pleural Mesothelioma

The Lancet Oncology


Additional Info

The Lancet Oncology
Tumour Treating Fields in Combination With Pemetrexed and Cisplatin or Carboplatin as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma (STELLAR): A Multicentre, Single-Arm Phase 2 Trial
Lancet Oncol 2019 Oct 15;[EPub Ahead of Print], GL Ceresoli, JG Aerts, R Dziadziuszko, R Ramlau, S Cedres, JP van Meerbeeck, M Mencoboni, D Planchard, A Chella, L Crinò, M Krzakowski, J Rüssel, A Maconi, L Gianoncelli, F Grosso

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading